Clinical trials · Washington, D.C., DC
Solid Tumor Cancer clinical trials in Washington, D.C.
We’re tracking 264 recruiting solid tumor cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Fairfax, VirginiaAges 18 years+ - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Fairfax, VirginiaAges 18 years+ - NCT07807241RecruitingPhase 1
Study of MX006 for advanced tumors with B7-H3
This trial tests a new drug (MX006) in people with advanced or metastatic tumors that have a specific marker called B7-H3. The drug may work by targeting this marker to stop cancer growth. The study aims to see if MX006 is safe and effective in this patient group.
Fairfax, VirginiaAges 18 years+ - NCT07814248RecruitingPhase 1
TS-104 for advanced solid tumors
This trial tests a new drug called TS-104 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is given alone (not with other cancer treatments) to see if it can shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT07819136RecruitingPhase 1/Phase 2
REC-7735 for people with advanced solid tumors
This study tests a new drug called REC-7735 for people with solid tumors that have a specific genetic change (PIK3CA H1047R). The drug targets this change to try to stop the cancer from growing.
Fairfax, VirginiaAges 18 years+ - NCT06998407RecruitingPhase 1/Phase 2
Study of AVZO-023 for advanced solid tumors
This trial tests a new drug, AVZO-023, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if it can shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT06326411RecruitingPhase 1
Testing NST-628 pills for advanced solid tumors with RAS/MAPK changes
This trial tests an experimental pill called NST-628 for people with advanced solid tumors that have specific genetic changes in the RAS/MAPK pathway. The goal is to see if it is safe and effective when other treatments are no longer working.
Fairfax, VirginiaAges 18 years+ - NCT07488676RecruitingPhase 1/Phase 2
Study of ASP546C for stomach, pancreas, and other cancers
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
Fairfax, VirginiaAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Fairfax, VirginiaAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
Fairfax, VirginiaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Fairfax, VirginiaAges 12 years+ - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT06090266RecruitingPhase 1/Phase 2
Study of OR502 alone and with other cancer treatments
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Fairfax, VirginiaAges 18 years+ - NCT06480552RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Fairfax, VirginiaAges 18 years+ - NCT07356453RecruitingPhase 1
Study of PARG inhibitor FORX-428 for advanced solid tumors
This trial tests a new drug called FORX-428, which targets a protein called PARG, in people with advanced solid tumors. It is for patients whose cancer has not responded to prior treatments and who have specific genetic changes, such as BRCA mutations.
Fairfax, VirginiaAges 18 years+ - NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT06515990RecruitingPhase 1/Phase 2
DM005 for Advanced Solid Tumors
This study tests a new drug called DM005 for people with advanced solid tumors (like lung, stomach, colon, liver, pancreas, or head and neck cancer) that have not responded to or can't tolerate standard treatments. The goal is to see if DM005 is safe and how well it works.
Fairfax, VirginiaAges 18 years+ - NCT06581432RecruitingPhase 2
Zongertinib for advanced cancers with HER2 changes
This trial tests an experimental pill called zongertinib for people with different types of advanced solid tumors that have a specific genetic change called HER2. It's a treatment option when other therapies haven't worked, and it may help shrink or slow the cancer.
Fairfax, VirginiaAges 18 years+ - NCT06532565RecruitingPhase 1
Study of GS-2121 alone or with other drugs for advanced solid tumors
This trial tests a new drug, GS-2121, given alone or with other therapies, for adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT07612189RecruitingPhase 1
Testing NEOK002 for Advanced Solid Tumors
This trial tests a new cancer drug called NEOK002 that targets two proteins (EGFR and MUC1) found on certain cancer cells. It's designed for patients with advanced cancers that have spread and don't have standard treatment options available.
Fairfax, VirginiaAges 18 years+ - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Fairfax, VirginiaAges 18 years+ - NCT07094204RecruitingPhase 1
Study of ASP5834 for advanced solid tumors with KRAS changes
This study tests a new drug (ASP5834) for people with advanced solid tumors that have changes in the KRAS gene. The study looks for a safe and effective dose, and may help you if your standard treatments have stopped working.
Fairfax, VirginiaAges 18 years+
Hear when a new Solid Tumor Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Solid Tumor Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting solid tumor cancer studies listed above.
- NEXT Oncology · 9 studies
- NEXT Virginia · 4 studies
- Virginia Cancer Specialists · 2 studies
- Avenzo Therapeutics Recruiting Site
- Inova Schar Cancer Institute
- Inova Schar Cancer Institute Clinical Trials
- Maryland Oncology Hematology, P.A.
- NEXT - Virginia Cancer Specialists
What taking part in a solid tumor cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there solid tumor cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 264 recruiting solid tumor cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a solid tumor cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New solid tumor cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.